BRPI0921353A2 - método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com eficácia aperfeiçoada com relação á terapia com warfarina convencional. - Google Patents

método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com eficácia aperfeiçoada com relação á terapia com warfarina convencional.

Info

Publication number
BRPI0921353A2
BRPI0921353A2 BRPI0921353A BRPI0921353A BRPI0921353A2 BR PI0921353 A2 BRPI0921353 A2 BR PI0921353A2 BR PI0921353 A BRPI0921353 A BR PI0921353A BR PI0921353 A BRPI0921353 A BR PI0921353A BR PI0921353 A2 BRPI0921353 A2 BR PI0921353A2
Authority
BR
Brazil
Prior art keywords
treating
salt
over conventional
improved efficacy
efficacy over
Prior art date
Application number
BRPI0921353A
Other languages
English (en)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0921353A2 publication Critical patent/BRPI0921353A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0921353A 2008-11-11 2009-11-10 método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com eficácia aperfeiçoada com relação á terapia com warfarina convencional. BRPI0921353A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11341308P 2008-11-11 2008-11-11
US23756609P 2009-08-27 2009-08-27
PCT/EP2009/064875 WO2010055023A1 (en) 2008-11-11 2009-11-10 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy

Publications (1)

Publication Number Publication Date
BRPI0921353A2 true BRPI0921353A2 (pt) 2015-12-29

Family

ID=41463077

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921353A BRPI0921353A2 (pt) 2008-11-11 2009-11-10 método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com eficácia aperfeiçoada com relação á terapia com warfarina convencional.

Country Status (16)

Country Link
US (2) US20110251160A1 (pt)
EP (1) EP2358367A1 (pt)
JP (1) JP2013510074A (pt)
KR (1) KR20110082563A (pt)
CN (2) CN102209545A (pt)
AR (1) AR074108A1 (pt)
AU (1) AU2009315731A1 (pt)
BR (1) BRPI0921353A2 (pt)
CA (1) CA2738885A1 (pt)
CL (1) CL2011000805A1 (pt)
IL (1) IL211854A0 (pt)
MX (1) MX2011004534A (pt)
NZ (1) NZ592613A (pt)
RU (1) RU2530645C2 (pt)
TW (1) TW201022238A (pt)
WO (1) WO2010055023A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358368A1 (en) 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
WO2011156587A2 (en) * 2010-06-09 2011-12-15 Daiichi Sankyo, Inc. Methods and systems for anticoagulation risk-benefit evaluations
DK2550966T3 (en) * 2011-07-25 2017-02-06 Dritte Patentportfolio Beteili Dabigatran amidoxic acid esters as prodrugs and their use as a drug
CN103127109B (zh) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 含达比加群酯或其盐和水合物的药用组合
RU2595238C1 (ru) * 2015-05-18 2016-08-20 Галина Александровна Суханова Способ лечения подострых венозных тромбозов различной локализации
RU2762945C1 (ru) * 2021-03-02 2021-12-24 Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии И Реабилитологии" (Фнкц Рр) Способ антикоагулянтной терапии и профилактики тромботических осложнений у пациентов с тяжелым повреждением головного мозга в хроническом критическом состоянии

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093881A2 (en) * 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応

Also Published As

Publication number Publication date
AU2009315731A1 (en) 2010-05-20
WO2010055023A1 (en) 2010-05-20
US20110251160A1 (en) 2011-10-13
AR074108A1 (es) 2010-12-22
KR20110082563A (ko) 2011-07-19
IL211854A0 (en) 2011-06-30
NZ592613A (en) 2013-06-28
JP2013510074A (ja) 2013-03-21
CN103340860A (zh) 2013-10-09
TW201022238A (en) 2010-06-16
CL2011000805A1 (es) 2011-10-28
MX2011004534A (es) 2011-05-24
EP2358367A1 (en) 2011-08-24
RU2011123367A (ru) 2012-12-20
US20140045898A1 (en) 2014-02-13
RU2530645C2 (ru) 2014-10-10
CA2738885A1 (en) 2010-05-20
CN102209545A (zh) 2011-10-05

Similar Documents

Publication Publication Date Title
BRPI0921354A2 (pt) método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com aprimorada eficácia em relação à terapia convencional com varfarina.
BRPI0619586A2 (pt) método para o tratamento ou prevenção de um distúrbio associado com cd40
BRPI0921479A2 (pt) método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com aprimorado perfil de segurança em relação à terapia convencional com varfarina
BRPI0717757A2 (pt) Derivado de haloalquilsulfoanilida ou um sal do mesmo, herbicida, e, método para usar um herbicida
BRPI0923861A2 (pt) Compostos e métodos para inibir o antiporte nhe-mediado no tratamento de distúrbios associados com a retenção de líquidos ou com a sobrecarga de sal e distúrbios do trato gastrointestinal.
BRPI1008672A2 (pt) método para tratar um furo de poço.
MX283613B (es) Metodo para tratar agua residual o agua producida.
BRPI0815747A2 (pt) Método para tratar água residual, e, método para intensificar as operações de tratamento de água residual.
BRPI0913114A2 (pt) Composição herbicida, e, métodos para controlar vegetação indesejável e para tratamento de queimada de vegetação indesejável culturas
BRPI0912337A2 (pt) composto método para melhorar memória em paciente, e, método para tratar condições
BRPI0920141A2 (pt) sistema e método para tratar uma formação de subsuperfície.
BRPI0814889A2 (pt) tratamento com ligantes alfa7-seletivos.
BRPI0717218A2 (pt) inibidor da ativaÇço, e, mÉtodo para previnir ou tratat um sintoma ou doenÇa.
BRPI0820525A2 (pt) Método aparelho e produto de programa para fundir sessões de comunicação em um ims
BRPI0914581A2 (pt) solução aquosa e kit para sanitizar produto, e, método para tratar produto
PT2644205T (pt) Direcionamento a abcb5 para tratamento oncológico
BRPI0911400A2 (pt) Método para controlar ervas daninhas aquáticas submersas.
EP2081437A4 (en) METHODS OF TREATING OR PREVENTING INFESTATION
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI0919587A2 (pt) método para documentar tratamento de animal, e , produto de software
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
FI20040011L (fi) Menetelmä pintojen käsittelemiseksi
BRPI0812892A2 (pt) Método para tratar fluxos de líquidos em uma fábrica de polpa química.
BRPI0718324A2 (pt) Métodos para o tratamento de depressão.
DK2131841T3 (da) Fremgangsmåder til behandling af akut smerte

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.